Feasibility study of postoperative adjuvant carboplatin plus nab-paclitaxel for complete resected pathological stage II/IIIA non-small cell lung cancer - FASTnab

Anticancer Drugs. 2017 Aug;28(7):795-800. doi: 10.1097/CAD.0000000000000512. Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab. Saji H(1), Marushima H, Miyazawa T, Sakai H, Kimura H, Kurimoto N, Nakamura H. Author information: (1)Department of Chest Surgery, St Marianna University School of Medicine, Kawasaki, Japan. The aim of this study was to determine the feasibility of adjuvant administration of nab-paclitaxel (nab-P) plus carboplatin and for completely resected patients with stage IB, II, and IIIA non-small-cell lung cancer (NSCLC) (FAST-nab study, UMIN000011225). Twenty-nine eligible NSCLC patients received surgical resection for pathological stage IB, II, or IIIA, followed by postoperative adjuvant chemotherapy with modified 3-week cycles of either nab-P (100mg/m) on days 1 and 8, followed by carboplatin area (area under the curve=6) on day 1. Twenty-two (75.9%) of the 29 patients enrolled completed four cycles of this regimen. The most common grade 3 or 4 adverse event experienced during the nab-P plus carboplatin was neutropenia (34.5%), followed by anemia (13.8%). No grade 3 or 4 nonhematologic adverse event was observed during this chemotherapy. The median time to disease recurrence survival was 21 (95% confidence interval: 16-26) months. The administration of modified nab-P plus carboplatin was considered an attractive alternative regimen that was safe and well tolerated as a postoperative adjuvant chemotherapy for completed resected NSCLC. DOI: 10.1097/CAD.0000000000000512 PMID: 28538017